Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Annals of Oncology - Tập 15 - Trang 440-449 - 2004
M.E.R. O’Brien1, N. Wigler2, M. Inbar2, R. Rosso3, E. Grischke4, A. Santoro5, R. Catane6, D.G. Kieback7, P. Tomczak8, S.P. Ackland9, F. Orlandi10, L. Mellars11, L. Alland11, C. Tendler11
1Kent Cancer Center, Maidstone, UK
2Ichilov Hospital, Tel Aviv, Israel
3Oncologia Medica I Ist., Genova, Italy
4Frauenklinik der Ruprecht-Karls-Universitat Vosstrasse, Heidelberg, Germany
5OncologiaMedica & Ematologie, Istituto Clinico Humanitas, Rozzano (MI), Italy
6Sha’are Zedek Medical Center, Jerusalem, Israel.
7Maastricht University Medical Center, Maastricht, The Netherlands
8Oncology Clinic, Poznan, Poland
9Newcastle Mater MisericordiaeHospital, Waratah, Australia
10HospitalDipreca, Santiago, Chile
11Schering-PloughResearch Institute, Kenilworth, NJ, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 15

440-449

Thông tin tác giả